RFA's as of March 10, 2021
| SARS-CoV-2, COVID-19 and Consequences of Alcohol Use (R21 Clinical Trial Not Allowed) | 4/15/2021 | R21 | RFA-AA-21-004 | https://grants.nih.gov/grants/guide/rfa-files/RFA-AA-21-004.html | NIAAA |
| SARS-CoV-2, COVID-19 and Consequences of Alcohol Use (R01 Clinical Trial Not Allowed) | 4/15/2021 | R01 | RFA-AA-21-002 | https://grants.nih.gov/grants/guide/rfa-files/RFA-AA-21-002.html | NIAAA |
| SARS-CoV-2, COVID-19 and Consequences of Alcohol Use (R03 Clinical Trial Not Allowed) | 4/15/2021 | R03 | RFA-AA-21-003 | https://grants.nih.gov/grants/guide/rfa-files/RFA-AA-21-003.html | NIAAA |
| Integrative Neuroscience Initiative on Alcoholism (INIA) Consortia (U01 Clinical Trial Optional) | 5/27/2021 | U01 | RFA-AA-20-013 | https://grants.nih.gov/grants/guide/rfa-files/RFA-AA-20-013.html | NIAAA |
| Integrative Neuroscience Initiative on Alcoholism (INIA) Consortia Research Resource (U24) (Clinical Trial Optional) | 5/27/2021 | U24 | RFA-AA-20-012 | https://grants.nih.gov/grants/guide/rfa-files/RFA-AA-20-012.html | NIAAA |
| Integrative Neuroscience Initiative on Alcoholism (INIA) Consortia Administrative Resource Core (U24) (Clinical Trial Optional) | 5/27/2021 | U24 | RFA-AA-20-011 | https://grants.nih.gov/grants/guide/rfa-files/RFA-AA-20-011.html | NIAAA |
| Single Cell Opioid Responses in the Context of HIV (SCORCH) Program Expansion: CNS Data Generation for Chronic Opioid, Methamphetamine, and/or Cocaine Exposures (U01 Clinical Trial Not Allowed) | 7/21/2021 | U01 | RFA-DA-21-019 | https://grants.nih.gov/grants/guide/rfa-files/RFA-DA-21-019.html | NIDA |
| Exploiting in vivo or in situ imaging approaches to understand HIV-relevant processes in the context of substance use disorders (R61/R33 Clinical Trials Optional) | 8/14/2021 | R61/R33 | RFA-DA-21-005 | https://grants.nih.gov/grants/guide/rfa-files/RFA-DA-21-005.html | NIDA |
| HEAL Initiative: Americas Startups and Small Businesses Build Technologies to Stop the Opioid Epidemic (R41/R42 - Clinical Trial Optional) | 9/9/2021 | R41/R42 | RFA-DA-19-020 | https://grants.nih.gov/grants/guide/rfa-files/RFA-DA-19-020.html | NIDA |
| HEAL Initiative: Americas Startups and Small Businesses Build Technologies to Stop the Opioid Epidemic (R43/R44 - Clinical Trial Optional) | 9/9/2021 | R43/R44 | RFA-DA-19-019 | https://grants.nih.gov/grants/guide/rfa-files/RFA-DA-19-019.html | NIDA |
| NIH Blueprint for Neuroscience Research: Tools and Technologies to Explore Nervous System Biomolecular Condensates (R21 Clinical Trial Not Allowed) | 9/16/2021 | R21 | RFA-DA-22-008 | https://grants.nih.gov/grants/guide/rfa-files/RFA-DA-22-008.html | NIDA |
| High-throughput Discovery and Validation of Novel Signal Transducers or Small Molecules that Modulate Opioid or other Substance Use Disorder Relevant Pathways (R01 - Clinical Trials Not Allowed) | 9/16/2021 | R01 | RFA-DA-22-006 | https://grants.nih.gov/grants/guide/rfa-files/RFA-DA-22-006.html | NIDA |
| Exploratory studies to investigate mechanisms of HIV infection, replication, latency, and/or pathogenesis in the context of substance use disorders (R61/R33 - Clinical Trial Not Allowed) | 7/15/2022 | R61/R33 | RFA-DA-22-004 | https://grants.nih.gov/grants/guide/rfa-files/RFA-DA-22-004.html | NIDA |
| BRAIN Initiative: Tools for Germline Gene Editing in Marmosets (U01 - Clinical Trial Not Allowed) | 10/15/2022 | U01 | RFA-DA-21-006 | https://grants.nih.gov/grants/guide/rfa-files/RFA-DA-21-006.html | NIDA |
| Advancing technologies to improve delivery of pharmacological, gene editing, and other cargoes for HIV and SUD mechanistic or therapeutic research (R01- Clinical Trial Optional) | 10/26/2022 | R01 | RFA-DA-22-010 | https://grants.nih.gov/grants/guide/rfa-files/RFA-DA-22-010.html | NIDA |